MicroRNA expression profiles in familial hypertrophic cardiomyopathy with myosin-binding protein C3 (MYBPC3) gene mutations

被引:6
|
作者
Lin, Li-rong [1 ,2 ]
Hu, Xue-qun [1 ,3 ]
Lu, Li-hong [1 ,2 ]
Dai, Jia-zhen [1 ]
Lin, Ning-ning [1 ]
Wang, Re-hua [1 ,2 ]
Xie, Zhang-xin [1 ,4 ]
Chen, Xue-mei [1 ,2 ]
机构
[1] Fujian Med Univ, Shengli Clin Med Coll, Fuzhou 350001, Peoples R China
[2] Fujian Prov Hosp, Dept Cardiol, Fuzhou 350001, Peoples R China
[3] Fujian Med Univ, Dept Neurosurg, Affiliated Hosp 1, Fuzhou 350001, Peoples R China
[4] Fujian Prov Hosp, Dept Emergency, Fuzhou 350001, Peoples R China
关键词
Familial hypertrophic cardiomyopathy; MYBPC3; Gene mutation; MicroRNA-sequencing; CARDIAC-HYPERTROPHY; INHIBITION; DIAGNOSIS; CHILDREN;
D O I
10.1186/s12872-022-02714-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Familial hypertrophic cardiomyopathy (FHCM) is an autosomal dominant inherited disease caused by mutations in genes encoding cardiac sarcomere proteins. MicroRNAs (miRNAs) play an important role in the pathogenesis of FHCM. In the present study, we aimed to determine the miRNA profile in FHCM patients with myosin-binding protein C3 (MYBPC3) gene mutations. We recruited three FHCM patients and age- and sex-matched controls. The three probands all had hypertrophic obstructive cardiomyopathy with severe myocardial hypertrophy, and two of the three had a history of sudden cardiac death, representing a "malignant" phenotype. We then compared the miRNA expression profiles of three FHCM patients carrying MYBPC3 gene mutations with those of the normal control group using miRNA sequencing technology. Differentially expressed miRNAs were verified using real-time polymerase chain reaction (qPCR). Target genes and signaling pathways of the identified differentially expressed miRNAs were predicted using bioinformatics analysis. A total of 33 significantly differentially expressed miRNAs were detected in the peripheral blood of the three probands, of which 28 were upregulated, including miR-208b-3p, and 5 were downregulated. Real-time PCR confirmed the upregulated expression of miR-208b-3p in FHCM patients (P < 0.05). Bioinformatics analysis showed that miR-208b-3p was mainly enriched in 79 target genes including UBE2V2, MED13, YBX1, CNKSR2, GATA4, andSOX5/6, et al. Gene ontology (GO) analysis of target genes showed that miR-208b was mainly involved in the processes of negative regulation of transcription from RNA polymerase II promoter, and regulation of transcription, DNA templated. Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis revealed that the target genes regulated by miR-208b-3p were mainly involved in the Wnt signaling pathway. These findings suggest that FHCM patients with MYBPC3 gene mutations have a specific miRNA expression profile, and that miR-208b-3p is significantly upregulated in cardiac hypertrophy. Our results also indicate that miRNA-208b-3p activates the Wnt signaling pathway through its target gene to promote cardiac hypertrophy.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Identification of founder MYBPC3 gene mutations in hungarian patients with hypertrophic cardiomyopathy
    Tringer, A.
    Hategan, L.
    Csanyi, B.
    Borbas, J.
    Palinkas, E.
    Nagy, V.
    Hegedus, Z.
    Nagy, I.
    Forster, T.
    Sepp, R.
    EUROPEAN JOURNAL OF HEART FAILURE, 2019, 21 : 55 - 55
  • [32] MicroRNA transcriptome profiling in cardiac tissue of hypertrophic cardiomyopathy patients with MYBPC3 mutations
    Kuster, Diederik W. D.
    Mulders, Joyce
    ten Cate, Folkert J.
    Michels, Michelle
    dos Remedios, Cristobal G.
    Martins, Paula A. da Costa
    van der Velden, Jolanda
    Oudejans, Cees B. M.
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2013, 65 : 59 - 66
  • [33] Protein haploinsufficiency drivers identify MyBPC3 mutations that cause hypertrophic cardiomyopathy
    Pricolo, Maria Rosaria
    Suay-Corredera, Carmen
    Velazquez-Carrera, Diana
    Herrero-Galan, Elias
    Delgado, Javier
    Garcia-Pavia, Pablo
    Monserrat, Lorenzo
    Frisso, Giulia
    Alegre-Cebollada, Jorge
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2020, 22 (0N) : N83 - N83
  • [34] An Update on MYBPC3 Gene Mutation in Hypertrophic Cardiomyopathy
    Tudurachi, Bogdan-Sorin
    Zavoi, Alexandra
    Leonte, Andreea
    Tapoi, Laura
    Ureche, Carina
    Birgoan, Silviu Gabriel
    Chiuariu, Traian
    Anghel, Larisa
    Radu, Rodica
    Sascau, Radu Andy
    Statescu, Cristian
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (13)
  • [35] Drosophila models of familial hypertrophic cardiomyopathy associated with human cardiac myosin-binding protein C mutations
    Mokrane, MA
    Flavigny, J
    Roder, L
    Schwartz, K
    Plovant, M
    Carrier, L
    Semeriva, M
    CIRCULATION, 2000, 102 (18) : 33 - 33
  • [36] How do MYBPC3 mutations cause hypertrophic cardiomyopathy?
    Steven Marston
    O’Neal Copeland
    Katja Gehmlich
    Saskia Schlossarek
    Lucie Carrrier
    Journal of Muscle Research and Cell Motility, 2012, 33 : 75 - 80
  • [37] Adverse events in families with hypertrophic or dilated cardiomyopathy and mutations in the MYBPC3 gene
    Ehlermann, Philipp
    Weichenhan, Dieter
    Zehelein, Jorg
    Steen, Henning
    Pribe, Regina
    Zeller, Raphael
    Lehrke, Stephanie
    Zugck, Christian
    Ivandic, Boris T.
    Katus, Hugo A.
    BMC MEDICAL GENETICS, 2008, 9
  • [38] Morphologic characteristics of hypertrophic cardiomyopathy of the elderly with cardiac myosin-binding protein C gene mutations
    Hirota, Takayoshi
    Kitaoka, Hiroaki
    Kubo, Toru
    Okawa, Makoto
    Furuno, Takashi
    Doi, Yoshinori L.
    CIRCULATION JOURNAL, 2006, 70 (07) : 875 - 879
  • [39] How do MYBPC3 mutations cause hypertrophic cardiomyopathy?
    Marston, Steven
    Copeland, O'Neal
    Gehmlich, Katja
    Schlossarek, Saskia
    Carrrier, Lucie
    JOURNAL OF MUSCLE RESEARCH AND CELL MOTILITY, 2012, 33 (01) : 75 - 80
  • [40] Cardiac myosin-binding protein C and hypertrophic cardiomyopathy
    Carrier, L
    Bonne, G
    Schwartz, K
    TRENDS IN CARDIOVASCULAR MEDICINE, 1998, 8 (04) : 151 - 157